Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome

Simple item page
dc.contributor.authorOni-Orisan, A.
dc.contributor.authorCresci, S.
dc.contributor.authorJones, P.G.
dc.contributor.authorTheken, K.N.
dc.contributor.authorSpertus, J.A.
dc.contributor.authorLee, C.R.
dc.date.issued2018
dc.description.abstractInhibition of soluble epoxide hydrolase (sEH, EPHX2) elicits potent cardiovascular protective effects in preclinical models of ischemic cardiovascular disease (CVD), and genetic polymorphisms in EPHX2 have been associated with developing ischemic CVD in humans. However, it remains unknown whether EPHX2 variants are associated with prognosis following an ischemic CVD event. We evaluated the association between EPHX2 p.Lys55Arg and p.Arg287Gln genotype with survival in 667 acute coronary syndrome (ACS) patients. No association with p.Arg287Gln genotype was observed (P = 0.598). Caucasian EPHX2 Arg55 carriers (Lys/Arg or Arg/Arg) had a significantly higher risk of 5-year mortality (adjusted hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.01-2.55, P = 0.045). In an independent population of 2712 ACS patients, this association was not replicated (adjusted HR 0.92, 95% CI 0.70-1.21, P = 0.559). In a secondary analysis, Caucasian homozygous Arg55 allele carriers (Arg/Arg) appeared to exhibit a higher risk of cardiovascular mortality (adjusted HR 2.60, 95% CI 1.09-6.17). These results demonstrate that EPHX2 p.Lys55Arg and p.Arg287Gln polymorphisms do not significantly modify survival after an ACS event. Investigation of other sEH metabolism biomarkers in ischemic CVD appears warranted.
dc.description.statementofresponsibilityAkinyemi Oni-Orisan, Sharon Cresci, Philip G.Jones, Katherine N.Thekene John A.Spertusdf Craig R.Lee
dc.identifier.citationProstaglandins and Other Lipid Mediators, 2018; 138:15-22
dc.identifier.doi10.1016/j.prostaglandins.2018.07.005
dc.identifier.issn1098-8823
dc.identifier.issn2212-196X
dc.identifier.orcidSpertus, J.A. [0000-0001-9485-0652] [0000-0002-2839-2611]
dc.identifier.urihttps://hdl.handle.net/2440/132698
dc.language.isoen
dc.publisherElsevier
dc.rights© 2018 Elsevier Inc. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.prostaglandins.2018.07.005
dc.subjectSoluble epoxide hydrolase; eicosanoids; polymorphism; prognosis; cardiovascular disease; humans; ischemic; EET
dc.subject.meshHumans
dc.subject.meshEpoxide Hydrolases
dc.subject.meshPrognosis
dc.subject.meshSurvival Rate
dc.subject.meshAmino Acid Substitution
dc.subject.meshGene Frequency
dc.subject.meshGenotype
dc.subject.meshPolymorphism, Single Nucleotide
dc.subject.meshAged
dc.subject.meshMiddle Aged
dc.subject.meshAfrican Americans
dc.subject.meshEuropean Continental Ancestry Group
dc.subject.meshFemale
dc.subject.meshMale
dc.subject.meshAcute Coronary Syndrome
dc.subject.meshKaplan-Meier Estimate
dc.titleAssociation between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Biochemistry publications